NEW YORK (GenomeWeb News) – Myriad Genetics' fiscal second-quarter revenues increased 21 percent year over year, the Salt Lake City firm reported after the close of the market on Tuesday.

Total revenues for the three months ended Dec. 31, 2012 came in at $149.1 million, up from $122.8 million in the year ago period, and beating the average analyst estimate of $143.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.